These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

229 related articles for article (PubMed ID: 16925744)

  • 21. Pharmacologic management of urinary incontinence, voiding dysfunction, and overactive bladder.
    Saks EK; Arya LA
    Obstet Gynecol Clin North Am; 2009 Sep; 36(3):493-507. PubMed ID: 19932412
    [TBL] [Abstract][Full Text] [Related]  

  • 22. How sudden is a compelling desire to void? An observational cystometric study on the suddenness of this sensation.
    De Wachter S; Wyndaele JJ
    BJU Int; 2008 Apr; 101(8):1000-3. PubMed ID: 18218058
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Observations relating to urinary sensation during detrusor overactivity.
    Lowenstein L; Pham T; Abbasy S; Kenton K; Brubaker L; Mueller ER; Shott S; Vardi Y; Gruenwald I; FitzGerald MP
    Neurourol Urodyn; 2009; 28(6):497-500. PubMed ID: 19090593
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Recommendations for the urodynamic examination in the investigation of non-neurological female urinary incontinence].
    Hermieu JF;
    Prog Urol; 2007 Nov; 17(6 Suppl 2):1264-84. PubMed ID: 18214138
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Selective beta-adrenoceptor agonists, calcium antagonists and potassium channel openers as a possible medical treatment of the overactive bladder and urge incontinence.
    Badawi JK; Langbein S
    Pharmazie; 2006 Mar; 61(3):175-8. PubMed ID: 16599254
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Local effects of antimuscarinics.
    Masuda H; Kim YT; Tyagi S; Chancellor MB; de Miguel F; Yoshimura N
    Urol Clin North Am; 2006 Nov; 33(4):511-8, ix-x. PubMed ID: 17011387
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Pain during ice water test distinguishes clinical bladder hypersensitivity from overactivity disorders.
    Mukerji G; Waters J; Chessell IP; Bountra C; Agarwal SK; Anand P
    BMC Urol; 2006 Dec; 6():31. PubMed ID: 17192176
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The effects of a type 4 phosphodiesterase inhibitor and the muscarinic cholinergic antagonist tolterodine tartrate on detrusor overactivity in female rats with bladder outlet obstruction.
    Kaiho Y; Nishiguchi J; Kwon DD; Chancellor MB; Arai Y; Snyder PB; Yoshimura N
    BJU Int; 2008 Mar; 101(5):615-20. PubMed ID: 18070178
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Current diagnostics and therapy of the overactive bladder and urge incontinence].
    Badawi JK; Langbein S
    Dtsch Med Wochenschr; 2005 Jun; 130(24):1503-6. PubMed ID: 15942840
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Persistence of therapeutic effect after repeated injections of botulinum toxin type A to treat incontinence due to neurogenic detrusor overactivity.
    Karsenty G; Reitz A; Lindemann G; Boy S; Schurch B
    Urology; 2006 Dec; 68(6):1193-7. PubMed ID: 17141831
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Urodynamic findings of the painful bladder syndrome/interstitial cystitis: a comparison with idiopathic overactive bladder.
    Kim SH; Kim TB; Kim SW; Oh SJ
    J Urol; 2009 Jun; 181(6):2550-4. PubMed ID: 19375103
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Treatment-resistant detrusor overactivity--underlying pharmacology and potential mechanisms.
    Andersson KE
    Int J Clin Pract Suppl; 2006 Dec; (151):8-16. PubMed ID: 17169005
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Botulinum toxin A detrusor injections in patients with neurogenic detrusor overactivity significantly decrease the incidence of symptomatic urinary tract infections.
    Gamé X; Castel-Lacanal E; Bentaleb Y; Thiry-Escudié I; De Boissezon X; Malavaud B; Marque P; Rischmann P
    Eur Urol; 2008 Mar; 53(3):613-8. PubMed ID: 17804150
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The impact of detrusor overactivity on bladder function in younger and older women.
    Pfisterer MH; Griffiths DJ; Rosenberg L; Schaefer W; Resnick NM
    J Urol; 2006 May; 175(5):1777-83; discussion 1783. PubMed ID: 16600758
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Urinary incontinence: anticholinergic treatment].
    Jimenez Cidre MA
    Rev Med Univ Navarra; 2004; 48(4):37-42. PubMed ID: 15810718
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Achieving continence with antimuscarinic therapy for overactive bladder: effects of baseline incontinence severity and bladder diary duration.
    Wein AJ; Khullar V; Wang JT; Guan Z
    BJU Int; 2007 Feb; 99(2):360-3. PubMed ID: 17155987
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Role of antimuscarinics in the treatment of nonneurogenic daytime urinary incontinence in children.
    Nijman RJ
    Urology; 2004 Mar; 63(3 Suppl 1):45-50. PubMed ID: 15013652
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Management of detrusor dysfunction in the elderly: changes in acetylcholine and adenosine triphosphate release during aging.
    Yoshida M; Miyamae K; Iwashita H; Otani M; Inadome A
    Urology; 2004 Mar; 63(3 Suppl 1):17-23. PubMed ID: 15013648
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Bladder sensations during filling cystometry are different according to urodynamic diagnosis.
    Digesu GA; Basra R; Khullar V; Hendricken C; Camarata M; Kelleher C
    Neurourol Urodyn; 2009; 28(3):191-6. PubMed ID: 18973145
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Pharmacological effects of solifenacin on human isolated urinary bladder.
    Masunaga K; Yoshida M; Inadome A; Murakami S; Sugiyama Y; Satoji Y; Maeda Y; Ueda S
    Pharmacology; 2008; 82(1):43-52. PubMed ID: 18434763
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.